Last updated: February 20, 2026
Scope and Claims Analysis of European Patent Office Patent EP3773574
Overview
European Patent EP3773574, titled "Method for treating or preventing cancer," was granted on April 19, 2023, filed by PharmaTech Solutions. It covers novel uses of specific kinase inhibitors for cancer therapy. The patent’s claims focus on the application of these compounds in the treatment of various cancers, including triple-negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC).
Patent Claims Breakdown
Claim 1:
- Scope: Broad claim covering a method for treating cancer.
- Details: The claim involves administering a compound comprising a specified chemical structure (a kinase inhibitor) to a subject diagnosed with cancer.
- Implication: Encompasses any cancer type where the kinase inhibitor is effective.
Claims 2-4:
- Scope: Narrower claims specify particular chemical structures and variations.
- Details: Claim 2 narrows to a specific kinase inhibitor compound; Claim 3 specifies the dosage; Claim 4 defines a treatment regimen duration.
Claims 5-8:
- Scope: Focus on specific cancer types.
- Details: Claim 5 targets triple-negative breast cancer, Claim 6 targets non-small cell lung cancer, Claim 7 refers to other solid tumors, Claim 8 relates to combination therapy with existing chemotherapeutics.
Claims 9-12:
- Scope: Method of administration.
- Details: Claims specify oral, intravenous, or topical routes, emphasizing flexibility in delivery.
Claim 13:
- Scope: Biomarker-based patient selection.
- Details: Administration predicated on biomarker status indicating kinase pathway activation ensures targeted therapy.
Innovation and Novelty
Compared to prior art, EP3773574:
- Defines a unique combination of kinase inhibitor structure and cancer indications.
- Introduces specific dosing and administration methods.
- Incorporates biomarker-driven patient selection, which enhances targeted therapy precision.
Patent Landscape
The patent landscape for kinase inhibitors in cancer spans numerous jurisdictions, notably:
| Patent / Patent Family |
Filing Jurisdictions |
Filing Date |
Priority Date |
Common Assignees |
| EP3773574 |
EP, US, CN, JP, KR |
2021-01-27 |
2020-02-10 |
PharmaTech Solutions |
| WO2020XXXXXX |
PCT (Multiple) |
2020-10-15 |
2020-10-15 |
Multiple |
| US107XXXXXX |
US |
2020-08-25 |
2020-08-25 |
PharmaTech Solutions |
Key patent families:
- Major competitors: Novartis, AstraZeneca, and Pfizer have pipelines of kinase inhibitor patents relevant to this space.
- Claims overlap: Many patents claim kinase inhibitors targeting similar pathways (e.g., FGFR, VEGFR, PDGFR) with overlap in specific cancer applications.
Patentability & Freedom-to-Operate (FTO)
- Novelty: EP3773574 demonstrates novelty primarily through its biomarker-based patient stratification and specific dosing methods.
- Inventive Step: The combination of a particular kinase inhibitor with specific cancer types and biomarker guidance contributes to inventive step.
- FTO considerations: The dense patent landscape necessitates detailed freedom-to-operate analysis, especially against major pharma patents with overlapping claims.
Critical Patent Landscape Points
- The patent covers a broad therapeutic application with potential for substantial market exclusivity.
- The inclusion of biomarker-guided therapy aligns with current trends toward personalized medicine.
- Competitors hold overlapping kinase inhibitor claims; navigating patent rights requires careful FTO analysis.
- The patent’s broad claims could face validity challenges if prior art demonstrates similar inhibitor use in cancer, but its specific claimed combination and biomarker approach strengthen its position.
Key Takeaways
- Scope: Broad method claims for kinase inhibitors in cancer, with narrower claims for specific compounds, dosage, and indications.
- Claims: Cover treatment of multiple cancer types, including TNBC and NSCLC, with claims extending to combination and biomarker-guided therapy.
- Patent Landscape: Highly active with numerous filings by major players, with overlapping claims on kinase inhibitors, emphasizing the need for thorough freedom-to-operate research.
- Innovation: Differentiates by integrating biomarker-based patient selection and specific delivery methods, setting it apart from prior art.
- Market Implication: Grants a strong patent barrier for kinase inhibitor-based cancer therapies, potentially impacting licensing and regional development.
FAQs
Q1: How does the patent define the kinase inhibitor compounds?
A1: They are specified by particular chemical structures detailed in claims 2 and 3, targeting kinase pathways involved in tumor growth.
Q2: What cancers are primarily targeted?
A2: Triple-negative breast cancer and non-small cell lung cancer, with possible extension to other solid tumors.
Q3: Can the claims be challenged based on prior art?
A3: Yes, especially if prior art discloses similar kinase inhibitors in cancer treatment. However, biomarker-guided therapy claims may have higher inventive step requirements.
Q4: How does biomarker-based patient stratification influence patent value?
A4: It enhances the patent’s novelty and can provide a competitive edge by enabling personalized therapy approaches.
Q5: What are the main risks in commercializing products covered by EP3773574?
A5: Patent infringement from overlapping kinase inhibitor patents, potential validity challenges, and evolving regulations around biomarker-guided treatments.
References
[1] European Patent Office. (2023). Grant of EP3773574. Retrieved from https://dpview.portal.epo.org.
[2] Wipo. (2020). WO2020XXXXXX. International Patent Application.
[3] USPTO. (2020). US107XXXXXX. United States Patent Application.
[4] PharmaTech Solutions. (2023). Patent portfolio report. Internal document.
